Ingredion Shareholders Approve Tate & Lyle All-Cash Acquisition

Shareholder Approval Milestone Reached for All-Cash Deal

Ingredion Incorporated disclosed that shareholders of Tate & Lyle PLC have approved the company's recommended all-cash acquisition of the entire issued and to be issued share capital of Tate & Lyle. The approval came on July 28, 2026, following votes at two shareholder meetings convened in England and Wales by order of the High Court of Justice. The Court Meeting specifically approved the scheme of arrangement, while a general meeting of shareholders voted to approve the resolutions necessary to implement the acquisition.

The acquisition was originally announced on June 8, 2026, and will proceed through a court-sanctioned scheme of arrangement under Part 26 of the UK Companies Act. This approach is standard for cross-border transactions involving UK-listed companies and provides a structured legal framework for implementing the combination. The shareholder votes represent a significant milestone in moving the transaction toward completion, though substantial regulatory hurdles remain ahead.

Expected Timeline and Closing Conditions

Ingredion stated that the acquisition is expected to be completed in the second half of 2027, subject to satisfaction or waiver of conditions specified in the Scheme document. The company identified material antitrust conditions and sanction of the Scheme by the Court as key closing conditions. These regulatory requirements represent the most significant remaining hurdles to completing the transaction within the expected timeframe.

The disclosure does not specify which antitrust authorities are reviewing the transaction or provide guidance on the expected timing of regulatory clearances. Investors may be watching for announcements regarding approval or challenges from regulatory agencies in major jurisdictions, as such developments could affect the expected closing date or deal certainty. The need for Court sanction, coupled with antitrust review, means the transaction timeline remains contingent on regulatory outcomes.

All-Cash Acquisition Structure and Implementation

The acquisition is structured as an all-cash offer for the entire issued and to be issued share capital of Tate & Lyle. The transaction will be implemented through a court-sanctioned scheme of arrangement, which provides a defined legal process under UK law for combining the two companies. This structure requires shareholder approval, which was obtained on July 28, 2026, followed by Court sanction as a condition to completion.

Ingredion disclosed that if it exercises its right to implement the acquisition by way of a takeover offer, such an offer would be made in compliance with applicable U.S. laws and regulations. The disclosure indicates flexibility in the implementation mechanism, though the primary path forward is through the Scheme. The all-cash consideration provides certainty of value to Tate & Lyle shareholders, eliminating equity consideration risk typically present in stock-for-stock transactions.

Regulatory and Legal Framework

The acquisition is being implemented under Part 26 of the UK Companies Act, which governs schemes of arrangement for UK-listed companies. This statutory framework provides a court-supervised process for restructuring transactions. The High Court of Justice in England and Wales must sanction the Scheme, and the filing discloses that the Court has already ordered the shareholder meetings to be convened, which have now occurred with positive votes.

The company noted in its disclosure that the acquisition must comply with applicable U.S. and UK laws and regulations. Material antitrust conditions identified in the Scheme document remain outstanding, indicating that competition authorities in one or more jurisdictions are reviewing the transaction. The filing does not provide specific details regarding which jurisdictions are conducting antitrust reviews or their expected timelines. Investors may be watching for regulatory announcements from agencies such as the Federal Trade Commission or UK competition authorities.

Cross-Border Transaction Complexity

This transaction represents a cross-border combination involving a Delaware-incorporated U.S. company acquiring a UK-listed public company. Such transactions typically involve compliance with regulatory regimes in multiple jurisdictions, including U.S. securities laws, UK financial conduct and merger regulations, and competition laws in various countries where the combined business operates. The filing indicates that both companies are subject to disclosure obligations in their respective home markets.

Ingredion disclosed the original announcement of the acquisition in a Form 8-K filed on June 9, 2026, demonstrating the company's compliance with U.S. securities disclosure obligations for material corporate events. The current disclosure, filed on July 28, 2026, provides U.S. investors with notification of shareholder approval in the UK, ensuring information symmetry across the capital markets where both companies' securities trade or have traded.

Earlier Announcement and Background

The filing references the original announcement of the recommended all-cash acquisition on June 8, 2026, which was reported in a Form 8-K filing on June 9, 2026. While the current disclosure does not repeat the full terms of the transaction, it confirms that the June announcement constituted the basis for the shareholder vote held on July 28, 2026. The approximately seven-week period between announcement and shareholder vote is consistent with timelines for UK public company transactions involving schemes of arrangement.

Ingredion described the acquisition as "recommended" in the filing, indicating that the boards of directors of both Ingredion and Tate & Lyle supported the transaction and recommended that shareholders approve it. This board-level endorsement is a standard component of UK takeover practice and likely contributed to the favorable shareholder vote. The company did not disclose the specific acquisition consideration or valuation metrics in this filing, referring instead to the June announcements for such details.

Information Purposes and Regulatory Disclaimers

Ingredion disclosed that the report is furnished for information purposes and does not constitute an offer, invitation, or solicitation to purchase securities or solicit votes or approval. The filing emphasizes that the acquisition will be made solely by means of the Scheme document, which will contain the full terms and conditions. If the company elects to implement the transaction through a takeover offer instead of a scheme, such offer would be made in compliance with applicable U.S. laws and regulations.

The regulatory disclaimers in the filing reflect the complex multi-jurisdictional nature of the transaction. The filing discloses that the information furnished in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act and is not subject to the liabilities of that Section. This limitation on liability is standard for Regulation FD disclosures. The company also stated that the information is not deemed incorporated by reference into other filings unless specifically stated otherwise.

Strategic Rationale and Business Combination

While the filing does not detail the strategic rationale for the acquisition, the transaction represents a significant combination in the ingredients and specialty products sector. Ingredion is a global ingredient solutions provider serving food, beverage, and industrial customers, while Tate & Lyle is a major ingredients and food additives company with substantial global operations. The all-cash structure and relatively short expected timeline from announcement to closing suggest that both companies' boards viewed the transaction as strategically important.

The all-cash consideration and recommended structure indicate that the boards believed the terms were fair and offered appropriate value to shareholders. The filing does not disclose the financial metrics underlying the transaction, such as the price per share, total transaction value, or pro forma financial impact. Investors seeking such information would need to refer to the June 8, 2026 announcement and Form 8-K filed on June 9, 2026, which the current disclosure references.

Investor Considerations Going Forward

The shareholder approval on July 28, 2026 clears a major procedural requirement, but the transaction remains subject to material conditions, particularly antitrust clearances and Court sanction. Investors may monitor regulatory proceedings in relevant jurisdictions to assess the likelihood and timing of final approval. Any announcements regarding challenges to the transaction from antitrust authorities or unexpected conditions could affect the expected closing timeline in the second half of 2027.

Ingredion shareholders and Tate & Lyle shareholders may be watching for updates on the completion status as regulatory processes unfold. The company indicated that further information regarding the transaction terms would be contained in the Scheme document or, if applicable, the takeover offer document. No additional financial guidance, pro forma financials, or strategic commentary regarding the combined business was provided in this disclosure, as it was limited to notification of shareholder approval.